Piperazine derivatives with CCR3 inhibiting activity

Details for Australian Patent Application No. 2005270305 (hide)

Owner Novartis AG

Inventors Legrand, Darren Mark

Agent Davies Collison Cave

Pub. Number AU-B-2005270305

PCT Pub. Number WO2006/015851

Priority 0417804.2 10.08.04 GB

Filing date 9 August 2005

Wipo publication date 16 February 2006

Acceptance publication date 10 September 2009

International Classifications

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 211/96 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 409/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

1 March 2007 PCT application entered the National Phase

  PCT publication WO2006/015851 Priority application(s): WO2006/015851

10 September 2009 Application Accepted

  Published as AU-B-2005270305

14 January 2010 Standard Patent Sealed

10 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005270306-Organic compounds

2005270302-Lipid metabolic and signalling pathways in the epidermis